Trinity Capital, an alternative asset manager, announced the commitment of $15 million in growth capital to Cagent Vascular, a leading developer of serration technology for vessel dilation in endovascular interventions. This capital augments $45 million of equity financing led by US Venture Partners in 2024.

Cagent Vascular is a medical device company pioneering innovative vascular treatment technologies. The company's flagship product, Serranator, helps improve angioplasty procedures by providing more predictable and controlled lumen gain with minimal dissection, while mitigating vessel recoil. Cagent Vascular aims to enhance patient outcomes and advance minimally invasive interventions by developing advanced endovascular solutions.

"We are excited to partner with Cagent Vascular as they continue to innovate and expand their platform of valuable solutions for physicians treating patients with peripheral artery disease," said Ryan Kaeding, Managing Director, Life Sciences at Trinity Capital.

"Cagent Vascular's Serration technology has been used in over 20,000 procedures and offers a growing library of compelling clinical evidence. We're confident this additional capital will help scale our commercial infrastructure and further accelerate clinical adoption," said Brian Walsh, Chairman and CEO of Cagent Vascular. "Trinity Capital's support is appreciated as we build a leading vascular company and make a difference in the lives of patients around the globe."